By Fineline Cube 
China‑based InnoCare Pharma Limited (SHA: 688428, HKG: 9969) today disclosed that its self‑developed antibody‑drug conjugate (ADC) ICP‑B794, which targets the tumor‑associated antigen B7‑H3, has successfully completed the first patient dose in its ongoing clinical trial.
How ICP‑B794 Works
- Design – ICP‑B794 couples a humanized anti‑B7‑H3 monoclonal antibody to a potent cytotoxic payload via a protease‑cleavable linker.
- Target Specificity – The linker strategy is engineered to release the drug only within the tumor microenvironment, thereby minimizing off‑target toxicity.
- Clinical Potential – The ADC is intended for solid‑tumor indications, including lung, esophageal, nasopharyngeal, head‑and‑neck squamous cell, and prostate cancers.
Preclinical Promise
- In murine models, ICP‑B794 outperformed existing B7‑H3‑directed agents, demonstrating robust tumor‑kill activity even against sizable lesions.
- No B7‑H3‑targeted therapies have yet gained regulatory approval worldwide, underscoring the significance of InnoCare’s platform.
Next Milestones
- Phase I Expansion – Following the first‑dose cohort, InnoCare will enroll additional patients to evaluate safety, tolerability, and preliminary efficacy.
- Biomarker Development – Companion diagnostics for B7‑H3 expression will be refined to identify optimal patient populations.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech